ArticleScience advances2025
Biohybrid nanorobots induce lactate isomer conversion to reverse the immune environment and promote tumor therapy.
Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Magnetically Guided Macrophage Immunobots Coordinate Iron-Metabolic Cascades and Immunogenic Ferroptosis for Tumor Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Advances in Nanoarchitectural Designs for Anticancer Drug Delivery to Deep Tumors.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Potassium-scavenging train-style nanorobots potentiate radiotherapy and reverse immunosuppression in glioblastoma.Journal of nanobiotechnology · 2026Article
- Unlocking miniature brilliance: micro/nanorobots for advanced dental theranostics.Journal of nanobiotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor cell glycolysis produces high levels of l-lactate (l-LA), creating an immunosuppressive microenvironment that enhances tumor stemness and impairs the efficacy of cancer therapies. Current strategies to reduce l-LA are limited by physical barriers in solid tumors and resource waste. This study presents an intelligent nanorobot that not only enhances tumor targeting and deep penetration but also reprograms the tumor immune microenvironment to convert l-LA into immunostimulatory d-lactate (d-LA). The nanorobot uses gold nanoparticles to bridge palladium (Pd) nanozymes and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.